MONTREAL--(BUSINESS WIRE)--“It is with determination that the entire Aplantex team follows its game plan with discipline to become a leading supplier of high-value molecules to the pharmaceutical, cosmetics, and agri-food industries in the context of the international growth of the circular economy,” said Patrick Charest, B. SC., P.Eng., CEO of Aplantex. “We are encouraged to continue our tireless efforts by the significant support from leading private investors as well as government and institutional sources that contributed to the success of our second round of financing,” he concludes.
Set up larger-scale production
Aplantex’s industrial platform uses photosynthetic plant replicators to produce a variety of molecules with antioxidant, anti-inflammatory, antimicrobial, and anti-aging properties. Plant replicators have proven their ability to produce bioactive molecules in a more environmentally responsible way than agriculture, conventional biotechnology platforms, or the conventional chemical industry. A recent study of the North American market confirms the interest of major players in the targeted industries for Aplantex molecules. As commercialization initiatives begin, the funds raised in this recent round of funding will be used to increase the production volume of the Boucherville research and production centre to meet this anticipated demand.
A significant contribution to the circular economy
Aplantex’s industrial platform is firmly part of the circular economy through local production that significantly reduces supply chains, automation at each stage of the process, loop reuse of multiple inputs, and use of renewable energy sources.
